Method of treating IgA nephropathy with atrasentan
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for atrasentan and nephropathy, which is applied in the field of treating IgA nephropathy with atrasentan, and can solve problems such as reducing the quality of life
Pending Publication Date: 2021-08-17
CHINOOK THERAPEUTICS INC
View PDF15 Cites 1 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
During this time, in addition to a decline in kidney function, patients exp...
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment approach 1
[0594] Embodiment 1. A method of inhibiting mesangial cell activation in a subject with IgA nephropathy comprising administering to the subject a therapeutically effective amount of atrasentan or a pharmaceutically acceptable salt thereof;
[0595] Wherein the subject has not been previously diagnosed with one or more of: diabetic nephropathy, HIV / AIDS or acute renal failure.
Embodiment approach 2
[0596] Embodiment 2. A method of treating IgA nephropathy comprising administering to a subject in need thereof a therapeutically effective amount of atrasentan or a pharmaceutically acceptable salt thereof;
[0597] Wherein the subject has not been previously diagnosed with one or more of: diabetic nephropathy, HIV / AIDS or acute renal failure.
Embodiment approach 3
[0598] Embodiment 3. A method of treating IgA nephropathy comprising administering to a subject in need thereof a therapeutically effective amount of atrasentan or a pharmaceutically acceptable salt thereof;
[0599] Wherein the subject does not suffer from one or more of the following: diabetic nephropathy, HIV / AIDS or acute renal failure.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
Provided herein is a method of treating IgA nephropathy comprising administering to a subject in need thereof a therapeutically effective amount of atrasentan or a pharmaceutically acceptable salt thereof. Also provided herein is a method of reducing kidney inflammation and/or fibrosis, reducing hematuria onset, stabilizing eGFR, reducing the number of disease attacks associated with IgA-nephropathy, delaying ESRD attacks, reducing proteinuria, and reducing fatigue in a subject suffering from IgA nephropathy, comprising administering to the subject a therapeutically effective amount of atrasentan or a pharmaceutically acceptable salt thereof. In some embodiments, a subject is not previously diagnosed with one or more of diabetic nephropathy, HIV/AIDS, HIV-related nephropathy, prostate cancer, or acute renal failure.
Description
[0001] Cross References to Related Applications [0002] This application claims U.S. Provisional Application No. 62 / 949,115, filed December 17, 2019, U.S. Provisional Application No. 63 / 005,003, filed April 3, 2020, U.S. Provisional Application No. 63 / 072,699, the priority of U.S. Provisional Application No. 63 / 084,739, filed September 29, 2020, and U.S. Provisional Application No. 63 / 125,205, filed December 14, 2020, incorporated by reference in their entirety. Background technique [0003] IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Aberrant IgA1 glycosylation results in elevated serum levels of galactose-deficient IgA1 (Gd-IgA1), which are recognized by glycan-specific IgA and IgG autoantibodies. Aggregates of immune complexes form and / or deposit in situ in the glomerular mesangium. This promotes the proliferation of mesangial cells, increases the synthesis of extracellular matrix proteins, cytokines, chemokines, and promotes the infil...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more